{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T15:47:30Z","timestamp":1762876050460,"version":"3.37.3"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,1,28]],"date-time":"2019-01-28T00:00:00Z","timestamp":1548633600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1007\/s10096-019-03488-0","type":"journal-article","created":{"date-parts":[[2019,1,28]],"date-time":"2019-01-28T00:47:07Z","timestamp":1548636427000},"page":"725-734","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Predictive factors of hepatitis C virus eradication after interferon-free therapy in HIV coinfection"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6018-9026","authenticated-orcid":false,"given":"Lourdes","family":"Dom\u00ednguez-Dom\u00ednguez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Otilia","family":"Bisbal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariano","family":"Matarranz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Lagarde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00d3scar","family":"Pinar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asunci\u00f3n","family":"Hernando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Lumbreras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"Rubio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Pulido","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,1,28]]},"reference":[{"key":"3488_CR1","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1001\/jama.2014.7734","volume":"312","author":"MS Sulkowski","year":"2014","unstructured":"Sulkowski MS, Naggie S, Lalezari J et al (2014) Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. JAMA 312:353\u2013361","journal-title":"JAMA"},{"key":"3488_CR2","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/S0140-6736(14)62483-1","volume":"385","author":"JM Molina","year":"2015","unstructured":"Molina JM, Orkin C, Iser DM et al (2015) Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study. Lancet 385:1098\u20131106","journal-title":"Lancet"},{"key":"3488_CR3","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1056\/NEJMoa1503153","volume":"373","author":"DL Wyles","year":"2015","unstructured":"Wyles DL, Ruane PJ, Sulkowski MS et al (2015) Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med 373:714\u2013725","journal-title":"N Engl J Med"},{"key":"3488_CR4","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1001\/jama.2015.1373","volume":"313","author":"A Osinusi","year":"2015","unstructured":"Osinusi A, Townsend K, Kohli A et al (2015) Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. JAMA 313:1232\u20131239","journal-title":"JAMA"},{"key":"3488_CR5","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa1501315","volume":"373","author":"S Naggie","year":"2015","unstructured":"Naggie S, Cooper C, Saag M et al (2015) Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med 373:705\u2013713","journal-title":"N Engl J Med"},{"key":"3488_CR6","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1001\/jama.2015.1328","volume":"313","author":"MS Sulkowski","year":"2015","unstructured":"Sulkowski MS, Eron JJ, Wyles D et al (2015) Ombitasvir, Paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1. A randomized trial. JAMA 313:1223\u20131231","journal-title":"JAMA"},{"issue":"Suppl.1","key":"3488_CR7","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/liv.13293","volume":"37","author":"R Flisiak","year":"2017","unstructured":"Flisiak R, Pogorzelska J, Flisiak-Jackiewicz M (2017) Hepatitis C: efficacy and safety in real life. Liver Int 37(Suppl.1):26\u201332","journal-title":"Liver Int"},{"key":"3488_CR8","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1111\/hiv.12429","volume":"18","author":"L Milazzo","year":"2017","unstructured":"Milazzo L, Lai A, Calvi E et al (2017) Direct-acting antivirals in hepatitis C virus (HCV)-infected and HCV\/HIV-coinfected patients: real-life safety and efficacy. HIV Med 18:284\u2013291","journal-title":"HIV Med"},{"doi-asserted-by":"publisher","unstructured":"Backus LI, Belperio PS, Shahoumian TA, Loomis TP, Mole LA (2016) Real-world effectiveness and predictors of sustained virological response with all-oral therapy in 21242 hepatitis C genotype-1 patients. Antivir Ther. https:\/\/doi.org\/10.3851\/IMP3117","key":"3488_CR9","DOI":"10.3851\/IMP3117"},{"key":"3488_CR10","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1111\/apt.13696","volume":"44","author":"LI Backus","year":"2016","unstructured":"Backus LI, Belperio PS, Shahoumian TA, Loomis TP, Mole LA (2016) Comparative effectiveness of ledipasvir \/ sofosbuvir +\/\u2212 ribavirin vs. ombitasvir \/ paritaprevir \/ ritonavir + dasabuvir +\/\u2212 ribavirin in 6961 genotype 1 patients treated in routine medical practice. Aliment Pharmacol Ther 44:400\u2013410","journal-title":"Aliment Pharmacol Ther"},{"key":"3488_CR11","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1093\/cid\/ciw119","volume":"62","author":"D Bello Del","year":"2016","unstructured":"Del Bello D, Cha A, Sorbera M et al (2016) Real-world sustained virologic response rates of sofosbuvir-containing regimens in patients coinfected with hepatitis C and HIV. Clin Infect Dis 62:1497\u20131504","journal-title":"Clin Infect Dis"},{"key":"3488_CR12","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1093\/cid\/cix111","volume":"64","author":"D Bhattacharya","year":"2017","unstructured":"Bhattacharya D, Belperio PS, Shahoumian TA et al (2017) Effectiveness of all-oral antiviral regimens in 996 human immunodeficiency virus\/hepatitis C virus genotype 1-coinfected patients treated in routine practice. Clin Infect Dis 64:1711\u20131720","journal-title":"Clin Infect Dis"},{"key":"3488_CR13","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jhep.2017.02.012","volume":"67","author":"L Piroth","year":"2017","unstructured":"Piroth L, Wittkop L, Lacombe K et al (2017) Efficacy and safety of direct-acting antiviral regimens in HIV\/HCV-co-infected patients\u2014French ANRS CO13 HEPAVIH cohort. J Hepatol 67:23\u201331","journal-title":"J Hepatol"},{"key":"3488_CR14","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1111\/hiv.12579","volume":"19","author":"J Bischoff","year":"2018","unstructured":"Bischoff J, Mauss S, Cordes C et al (2018) Rates of sustained virological response 12 weeks after the scheduled end of direct-acting antiviral (DAA)-based hepatitis C virus (HCV) therapy from the National German HCV registry: does HIV coinfection impair the response to DAA combination therapy? HIV Med 19:299\u2013307","journal-title":"HIV Med"},{"key":"3488_CR15","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/hep.29814","volume":"68","author":"J Berenguer","year":"2018","unstructured":"Berenguer J, Gil-Martin A, Jarrin I et al (2018) All-oral DAA therapy against HCV in HIV\/HCV-coinfected subjects in real-world practice: Madrid-CoRe findings. Hepatology 68:32\u201347","journal-title":"Hepatology"},{"key":"3488_CR16","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1053\/j.gastro.2013.02.039","volume":"144","author":"J Chen","year":"2013","unstructured":"Chen J, Florian J, Carter W et al (2013) Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies. Gastroenterology 144:1450\u20131455","journal-title":"Gastroenterology"},{"key":"3488_CR17","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/hep.27366","volume":"61","author":"EM Yoshida","year":"2015","unstructured":"Yoshida EM, Sulkowski MS, Gane EJ et al (2015) Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus. Hepatology 61:41\u201345","journal-title":"Hepatology"},{"key":"3488_CR18","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1093\/cid\/ciu865","volume":"60","author":"F Poordad","year":"2015","unstructured":"Poordad F, Agarwal K, Younes Z, Cohen D, Xie W, Podsadecki T (2015) Low relapse rate leads to high concordance of sustained virologic response (SVR) at 12 weeks with SVR at 24 weeks after treatment with ABT-450\/ritonavir, ombitasvir, and dasabuvir plus ribavirin in subjects with chronic hepatitis c virus genotype 1 infect. Clin Infect Dis 60:608\u2013610","journal-title":"Clin Infect Dis"},{"key":"3488_CR19","first-page":"154","volume":"15","author":"SV Burgess","year":"2016","unstructured":"Burgess SV, Hussaini T, Yoshida EM (2016) Concordance of sustained virologic response at weeks 4, 12 and 24 post-treatment of hepatitis C in the era of new oral direct-acting antivirals: a concise review. Ann Hepatol 15:154\u2013159","journal-title":"Ann Hepatol"},{"key":"3488_CR20","doi-asserted-by":"publisher","first-page":"S38","DOI":"10.1016\/j.jhep.2015.03.006","volume":"62","author":"P Mathurin","year":"2015","unstructured":"Mathurin P, Bataller R (2015) Trends in the management and burden of alcoholic liver disease. J Hepatol 62:S38\u2013S46","journal-title":"J Hepatol"},{"key":"3488_CR21","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1086\/521857","volume":"45","author":"S Vergara","year":"2007","unstructured":"Vergara S, Mac\u00edas J, Rivero A et al (2007) The use of transient elastometry for assessing liver fibrosis in patients with HIV and hepatitis C virus coinfection. Clin Infect Dis 45:969\u2013974","journal-title":"Clin Infect Dis"},{"key":"3488_CR22","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/j.jhep.2008.07.031","volume":"49","author":"J Mac\u00edas","year":"2008","unstructured":"Mac\u00edas J, Recio E, Vispo E et al (2008) Application of transient elastometry to differentiate mild from moderate to severe liver fibrosis in HIV\/HCV co-infected patients. J Hepatol 49:916\u2013922","journal-title":"J Hepatol"},{"key":"3488_CR23","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1097\/QAI.0b013e318157b0da","volume":"47","author":"L Valerio","year":"2008","unstructured":"Valerio L, Yazdanpanah Y, Poizot-Martin I et al (2008) Baseline CD4 cell count and outcome of pegylated interferon plus ribavirin therapy in HIV\/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr 47:50\u201355","journal-title":"J Acquir Immune Defic Syndr"},{"key":"3488_CR24","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/S1665-2681(19)31167-6","volume":"14","author":"T Ald\u00e1miz-Echevarr\u00eda","year":"2015","unstructured":"Ald\u00e1miz-Echevarr\u00eda T, Gonz\u00e1lez-Garc\u00eda J, Von Wichmann MA et al (2015) Association of baseline CD4+ cell count and HIV-RNA on sustained virologic response to interferon-ribavirin in HIV\/HCV coinfected patients. Ann Hepatol 14:464\u2013469","journal-title":"Ann Hepatol"},{"key":"3488_CR25","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1055\/s-0034-1371007","volume":"34","author":"JM Pawlotsky","year":"2014","unstructured":"Pawlotsky JM (2014) New hepatitis C virus (HCV) drugs and the hope for a cure: concepts in anti-HCV drug development. Semin Liver Dis 34:22\u201329","journal-title":"Semin Liver Dis"},{"key":"3488_CR26","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1093\/cid\/civ948","volume":"62","author":"B Simmons","year":"2016","unstructured":"Simmons B, Saleem J, Hill A, Riley RD, Cooke GS (2016) Risk of late relapse or reinfection with hepatitis C virus after achieving a sustained virological response: a systematic review and meta-analysis. Clin Infect Dis 62:683\u2013694","journal-title":"Clin Infect Dis"},{"key":"3488_CR27","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.jhep.2016.09.004","volume":"66","author":"P Ingiliz","year":"2017","unstructured":"Ingiliz P, Martin TC, Rodger A et al (2017) HCV reinfection incidence and spontaneous clearance rates in HIV-positive men who have sex with men in Western Europe. J Hepatol 66:282\u2013287","journal-title":"J Hepatol"},{"unstructured":"Ingiliz P, Christensen S, Schewe K et al (2017) High incidence of HCV reinfection in HIV-positive MSM in the DAA Era. [Abstract PS9\/5]. 16th European AIDS Conference. Milan, Italy","key":"3488_CR28"},{"key":"3488_CR29","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1177\/135965350701200412","volume":"12","author":"JA Mira","year":"2007","unstructured":"Mira JA, Rivero A, Santos I et al (2007) Rapid Virological response at week 4 predicts sustained response to Pegylated interferon plus ribavirin among HIV\/HCV Coinfected patients. Antivir Ther 12:523\u2013529","journal-title":"Antivir Ther"},{"key":"3488_CR30","doi-asserted-by":"publisher","first-page":"409.e5","DOI":"10.1016\/j.cmi.2016.12.034","volume":"23","author":"JA Pineda","year":"2017","unstructured":"Pineda JA, Morano-Amado LE, Granados R et al (2017) Week 4 response predicts sustained virological response to all-oral direct-acting antiviral-based therapy in cirrhotic patients with hepatitis C virus genotype 3 infection. Clin Microbiol Infect 23:409.e5\u2013409.e8","journal-title":"Clin Microbiol Infect"},{"key":"3488_CR31","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1016\/j.jhep.2015.08.010","volume":"63","author":"M Buti","year":"2015","unstructured":"Buti M, Riveiro-Barciela M, Esteban R (2015) Management of direct-acting antiviral agent failures. J Hepatol 63:1511\u20131522","journal-title":"J Hepatol"},{"key":"3488_CR32","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.drugpo.2017.05.025","volume":"47","author":"K Mason","year":"2017","unstructured":"Mason K, Dodd Z, Guyton M et al (2017) Understanding real-world adherence in the directly acting antiviral era: a prospective evaluation of adherence among people with a history of drug use at a community-based program in Toronto, Canada. Int J Drug Policy 47:202\u2013208","journal-title":"Int J Drug Policy"},{"key":"3488_CR33","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1097\/QAD.0000000000000903","volume":"30","author":"K Townsend","year":"2016","unstructured":"Townsend K, Petersen T, Gordon LA et al (2016) Effect of HIV co-infection on adherence to a 12-week regimen of hepatitis C virus therapy with ledipasvir and sofosbuvir. AIDS 30:261\u2013266","journal-title":"AIDS"},{"key":"3488_CR34","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1007\/s12072-015-9680-7","volume":"10","author":"T Petersen","year":"2016","unstructured":"Petersen T, Townsend K, Gordon LA et al (2016) High adherence to all-oral directly acting antiviral HCV therapy among an inner-city patient population in a phase 2a study. Hepatol Int 10:310\u2013319","journal-title":"Hepatol Int"},{"doi-asserted-by":"publisher","unstructured":"Puenpatom A, Hull M, McPheeters J, Schwebke K (2017) Treatment discontinuation, adherence, and real-world effectiveness among patients treated with Ledipasvir\/Sofosbuvir in the United States. Infect Dis Ther. https:\/\/doi.org\/10.1007\/s40121-017-0163-0","key":"3488_CR35","DOI":"10.1007\/s40121-017-0163-0"},{"key":"3488_CR36","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1093\/cid\/ciw379","volume":"63","author":"P Sogni","year":"2016","unstructured":"Sogni P, Gilbert C, Lacombe K et al (2016) All-oral direct-acting antiviral regimens in HIV\/hepatitis C virus-coinfected patients with cirrhosis are efficient and safe: real-life results from the prospective ANRS CO13-HEPAVIH cohort. Clin Infect Dis 63:763\u2013770","journal-title":"Clin Infect Dis"},{"key":"3488_CR37","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1097\/QAD.0000000000001465","volume":"31","author":"ML Montes","year":"2017","unstructured":"Montes ML, Olveira A, Ahumada A et al (2017) Similar effectiveness of direct-acting antiviral against hepatitis C virus in patients with and without HIV infection. AIDS 31:1253\u20131260","journal-title":"AIDS"}],"container-title":["European Journal of Clinical Microbiology &amp; Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10096-019-03488-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-019-03488-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-019-03488-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,11]],"date-time":"2022-09-11T00:53:53Z","timestamp":1662857633000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10096-019-03488-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,28]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["3488"],"URL":"https:\/\/doi.org\/10.1007\/s10096-019-03488-0","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"type":"print","value":"0934-9723"},{"type":"electronic","value":"1435-4373"}],"subject":[],"published":{"date-parts":[[2019,1,28]]},"assertion":[{"value":"13 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"- LDD has received payment for lectures from Abbvie, Gilead and Janssen, and she has received financial support for expert courses and congress by Merck Sharp and Dome, Gilead and Abbvie.- OB has received payments for lectures from AbbVie, Merck Sharp and Dome and Janssen, and she has received scholarship for expert courses and congress by Merck Sharp and Dome, Janssen, Bristol-Myers-Squibb, Gilead and Abbvie. Her work is currently supported by the Spanish AIDS Research Network (RD16\/0025\/0017) that is included in the Spanish I+D+I Plan and is cofinanced by ISCIII-Subdirecci\u00f3n General de Evaluaci\u00f3n and European Funding for Regional Development (FEDER).- MM reports honoraria for advisory boards from Abbvie and has received payment for lectures from AbbVie, Bristol-Myers-Squibb and Merck Sharp and Dome.- ML reports honoraria as speaker in educational programs sponsored by Janssen, ViiV, Gilead, Bristol-Myers-Squibb, Merck Sharp and Dome and Abbvie; has received scholarship for expert courses by Merck Sharp and Dome, Janssen and Abbvie; and has received financial support for national and international HIV courses (registration and travel assistance).- AH, OP and CL have no conflict of interest.- RR reports grants and payment for lectures from Abbott, Boehringer Ingelheim, Bristol-Myers-Squibb, Gilead, Janssen, Merck Sharp and Dome and ViiV.- FP has received honoraria for lectures and advisory boards from Abbvie, Gilead, Janssen and ViiV.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Patients signed an informed consent approved by the Ethics Committee belonging to the Biomedical Research Institute <i>Imas12<\/i> (University Hospital <i>12 de Octubre<\/i>) when included in the VIH-DOC cohort. This document allows clinical data recollection and analysis for observational study purposes.Data were anonymised and managed according to the Good Clinical Practice Guidelines published by the World Medical Association Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and informed consent"}}]}}